Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-12250-w
Abstract: This study aimed to assess the effectiveness, safety, and recurrence patterns of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma (ESCC) patients. A retrospective analysis of 79 eligible ESCC patients was conducted. Primary… read more here.
Keywords: treatment; immunotherapy; immunotherapy combined; cell ... See more keywords
Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14664
Abstract: This meta‐analysis aimed to compare the efficacy of immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line therapy for patients with programmed death ligand‐1 (PD‐L1)‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer (NSCLC). read more here.
Keywords: meta analysis; combined chemotherapy; chemotherapy versus; versus chemotherapy ... See more keywords
Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2024 at "BMC Cancer"
DOI: 10.1186/s12885-024-12340-4
Abstract: Immunotherapy or apatinib alone has been used as third-line adjuvant therapy for advanced or metastatic gastric/gastroesophageal junction (G/GEJ) tumors, but the efficacy of combining them with each other for the treatment of patients with advanced… read more here.
Keywords: combined apatinib; treatment; meta analysis; immunotherapy ... See more keywords
Real world effectiveness of immunotherapy combined with anti-angiogenic therapy in patients with anthracycline-resistant soft tissue sarcomas.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e23543
Abstract: e23543 Background: Soft tissue sarcomas are a heterogeneous group of malignant tumors of mesenchymal origin with more than 50 histologic subtypes. They have distinct molecular, genetic and clinical features and account for 1% of adult… read more here.
Keywords: therapy; immunotherapy combined; line; tissue sarcomas ... See more keywords
D-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Gastrointestinal Oncology"
DOI: 10.21037/jgo-24-824
Abstract: Background Immune checkpoint inhibitors (ICIs) combined with chemotherapy have emerged as a new choice for advanced and metastatic gastric cancer (GC) patients. Due to the lack of unified and effective predictive biomarkers, there is an… read more here.
Keywords: dimer group; immunotherapy combined; combined chemotherapy; advanced metastatic ... See more keywords
Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I–IIIA small-cell lung cancer: a retrospective single-arm clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thoracic Disease"
DOI: 10.21037/jtd-22-1287
Abstract: Background Immunotherapy, chemotherapy and surgery all have significant roles in the management of small-cell lung cancer (SCLC). Neoadjuvant immunotherapy combined with chemotherapy followed by surgery has shown encouraging efficacy for resectable SCLC with a good… read more here.
Keywords: immunotherapy; neoadjuvant immunotherapy; stage iiia; combined chemotherapy ... See more keywords